Literature DB >> 5025039

Multiple primary melanoma following administration of levodopa.

J L Skibba, J Pinckley, E F Gilbert, R O Johnson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5025039

Source DB:  PubMed          Journal:  Arch Pathol        ISSN: 0363-0153


× No keyword cloud information.
  21 in total

1.  The effect of L-dopa, noradrenalin and adrenalin on P-388 mouse leukemia, B-16 mouse melanoma and E 0771 mammary carcinoma.

Authors:  B Shohat; E Kott; B Bornstein
Journal:  Experientia       Date:  1975-01-15

2.  Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.

Authors:  J R Bianchine; L Sunyapridakul
Journal:  Drugs       Date:  1973       Impact factor: 9.546

3.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Authors:  Ilir Agalliu; Marta San Luciano; Anat Mirelman; Nir Giladi; Bjorg Waro; Jan Aasly; Rivka Inzelberg; Sharon Hassin-Baer; Eitan Friedman; Javier Ruiz-Martinez; Jose Felix Marti-Masso; Avi Orr-Urtreger; Susan Bressman; Rachel Saunders-Pullman
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

4.  Parkinson's disease, melanoma, and levodopa.

Authors:  J Fermaglich; P Delaney
Journal:  J Neurol       Date:  1977-06-13       Impact factor: 4.849

5.  Levodopa and melanoma: three cases and review of literature.

Authors:  F H Rampen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

6.  Treatment with diphenyl-pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death.

Authors:  Elisa Turriani; Diana F Lázaro; Sergey Ryazanov; Andrei Leonov; Armin Giese; Margarete Schön; Michael P Schön; Christian Griesinger; Tiago F Outeiro; Donna J Arndt-Jovin; Dorothea Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

7.  High prevalence of malignant melanoma in Israeli patients with Parkinson's disease.

Authors:  R Inzelberg; J M Rabey; E Melamed; R Djaldetti; A Reches; S Badarny; S Hassin-Baer; O Cohen; H Trau; J Aharon-Peretz; R Milo; M Schwartz; M Huberman; L Gilead; M Barchana; I Liphshiz; C Fitzer-Attas; N Giladi
Journal:  J Neural Transm (Vienna)       Date:  2011-02-05       Impact factor: 3.575

Review 8.  The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.

Authors:  Rivka Inzelberg; Simon D Israeli-Korn
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

9.  Family history of melanoma and Parkinson disease risk.

Authors:  X Gao; K C Simon; J Han; M A Schwarzschild; A Ascherio
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

10.  Lid melanoma and parkinsonism.

Authors:  S A Haider; V T Thaller
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.